Kaitlyn D’Onofrio

DocwireNews

A randomized trial found that lutikizumab, an anti-interleukin (IL)-1&alpha;/&beta; dual variable domain immunoglobulin, did not improve pain or imaging outcomes in patients with erosive hand osteoarthritis (HOA) when compared to placebo.For 24 weeks, patients received either placebo or lutikizumab 200 mg every two weeks. Eligible patients had &ge;1 erosive and &ge;3 tender and/or swollen hand joints. At the start of the trial and after 24 weeks, patients underwent bilateral hand radiographs and hand MRI of the hand most tender or swollen at baseline at baseline and week 26. A change in Australian/Canadian Osteoarthritis Hand Index (AUSCAN) pain subdomain score from baseline to 16 weeks was the primary endpoint, and covariance models were evaluated as continuous endpoints.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
News: Treatment with the IL-1&alpha;/&beta; inhibitor <a href="https://twitter.com/hashtag/lutikizumab?src=hash&amp;ref_src=twsrc%5Etfw">#lutikizumab</a> &lsquo;may not be effective&rsquo; for erosive hand <a href="https://twitter.com/hashtag/osteoarthritis?src=hash&amp;ref_src=twsrc%5Etfw">#osteoarthritis</a> &ndash; phase IIa <a href="https://twitter.com/hashtag/ClinicalTrial?src=hash&amp;ref_src=twsrc%5Etfw">#ClinicalTrial</a> results by Margreet Kloppenburg (from <a href="https://twitter.com/LUMC_Leiden?ref_src=twsrc%5Etfw">@LUMC_Leiden</a>) &amp; team. Full paper in <a href="https://twitter.com/ARD_BMJ?ref_src=twsrc%5Etfw">@ARD_BMJ</a> <a href="https://t.co/QL2qtDr7qj">https://t.co/QL2qtDr7qj</a>
&mdash; medwireNews (@medwireNews) <a href="https://twitter.com/medwireNews/status/1075413153821937665?ref_src=twsrc%5Etfw">December 19, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>Out of 132 randomized patients, 110 completed the trial (lutikizumab, n = 49; placebo, n = 61). After 16 weeks, AUSCAN pain scores did not significantly differ between the lutikizumab and placebo groups (least squares mean difference, 1.5 [95% CI &ndash;1.9 to 5.0]). Clinical and imaging endpoints also did not differ between the groups; pain, stiffness, grip strength and patient-reported outcomes were similar between lutikizumab and placebo patients. Lutikizumab patients had significantly lower serum high-sensitivity C reactive protein levels, IL-1&alpha; and IL-1&beta; levels, and blood neutrophils. Lutikizumab patients also had more cases of injection site reactions and neutropaenia, as well as discontinuations due to adverse events (lutikizumab, 4/64; placebo, 1/67).<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
In a phase 2a, <a href="https://twitter.com/hashtag/randomised?src=hash&amp;ref_src=twsrc%5Etfw">#randomised</a>, double-blind study in patients with erosive <a href="https://twitter.com/hashtag/HOA?src=hash&amp;ref_src=twsrc%5Etfw">#HOA</a>, treatment with lutikizumab did lead to adequate <a href="https://twitter.com/hashtag/interleukin?src=hash&amp;ref_src=twsrc%5Etfw">#interleukin</a>-1&alpha; (IL-1&alpha;) and IL-1&beta; blockage, but did not lead to improved <a href="https://twitter.com/hashtag/pain?src=hash&amp;ref_src=twsrc%5Etfw">#pain</a> or <a href="https://twitter.com/hashtag/imaging?src=hash&amp;ref_src=twsrc%5Etfw">#imaging</a> outcomes.<a href="https://t.co/Ra2ynUyDFy">https://t.co/Ra2ynUyDFy</a> <a href="https://t.co/ygU7pDWQxa">pic.twitter.com/ygU7pDWQxa</a>
&mdash; Annals of the Rheumatic Diseases (@ARD_BMJ) <a href="https://twitter.com/ARD_BMJ/status/1074429781251383297?ref_src=twsrc%5Etfw">December 16, 2018</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>One of the study&rsquo;s limitations was that it ended after 26 weeks; more time may have demonstrated &ldquo;a structural effect of lutikizumab&rdquo; and detected &ldquo;related pain and function improvement,&rdquo; according to the researchers. Researchers also did not measure joint synovial fluid levels of lutikizumab, IL-1&alpha; and/or IL-1&beta;, so IL-1&alpha; and IL-1&beta; concentrations may have been lowered to a level not detected radiographically or clinically. &ldquo;In addition, we have no adequate explanation for the low use of NSAIDs or analgesics, given the high average level of pain in patients at baseline,&rdquo; the study authors added.&ldquo;In conclusion, despite adequate systemic lutikizumab pharmacodynamic effects, lutikizumab did not significantly improve clinical outcomes or imaging outcomes in patients with erosive HOA, compared with placebo, suggesting that targeting IL-1 may be ineffective for the treatment of erosive HOA,&rdquo; the researchers wrote.<a href="https://proddocwire.wpengine.com/docwire-pick/fda-guidance-osteoarthritis/">FDA Guidance for Osteoarthritis</a><a href="https://proddocwire.wpengine.com/rheumatology/losing-weight-with-knee-osteoarthritis-more-is-better/">Losing Weight with Knee Osteoarthritis: More is Better</a><a href="https://proddocwire.wpengine.com/docwire-pick/future-of-medicine-picks/researchers-employ-nanotechnology-to-better-track-osteoarthritis-progression/">Researchers Employ Nanotechnology to Better Track Osteoarthritis Progression</a><a href="https://proddocwire.wpengine.com/general/increases-in-motor-cortical-excitability-during-mirror-visual-feedback-of-a-precision-grasp-is-influenced-by-vision-and-movement-of-the-opposite-limb/">Increases in motor cortical excitability during mirror visual feedback of a precision grasp is influenced by vision and movement of the opposite limb</a>Source: <a href="https://ard.bmj.com/content/early/2018/12/14/annrheumdis-2018-213336#">Annals of the Rheumatic Diseases</a>

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Drug Targeting IL-1 Not Effective in Treating Erosive HOA

Osteoarthritis

A randomized trial found that lutikizumab, an anti-interleukin (IL)-1α/β dual variable domain immunoglobulin, did not improve pain or imaging outcomes in patients with ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe